• HOME
  • RESEARCH
    • Biology and dysregulation of IncRNAs
    • Ribosomopathies
    • Epigenetic engineering
    • Engineering cellular immunotherapies
    • Drugging SARS-CoV2 RNA-protein interactions
    • Funding
  • PUBLICATIONS
  • WHO WE ARE
    • Principal Investigator
    • Members
    • Collaborators
    • Alumni
    • Positions Available
    • Lab News
    • Communities
  • MENTORSHIP
  • ENTREPRENEURSHIP
  • CONTACT US
Novina Lab - Engineering Biological Technologies into Therapies

Our Research

The Novina lab focuses on the fundamental biology of non-coding RNAs and their development as biomedical tools. We use these tools to study the biology of RNA-regulated processes and to accelerate the translation of biological discoveries into novel therapies. These areas have numerous biological, technical, and translational synergies. For instance, (1) we use our RNA discovery platform to identify non-coding RNAs and their interacting proteins relevant for cancers, bone marrow failure and immune cell function (2) identify RNAs and small molecules that inhibit these interactions and (3) use these inhibitors to model hematopoietic and cancer immunotherapies. (4) We also develop Cas9-based epigenetic editing tools to target coding and non-coding loci to model hematopoietic and cancer immunotherapies. Please click the icons below to learn more about each area of these programs.
Biology and dysregulation of IncRNAs
Picture
Epigenetic Engineering
Picture
Ribosomopathies 
Picture
Engineering cellular immunotherapies
Picture
Drugging SARS-CoV2 RNA-protein interactions
Picture
Funding 
Picture
 HOME | RESEARCH | PUBLICATIONS | WHO WE ARE | MENTORSHIP | ENTREPRENEURSHIP | SUPPORT US | CONTACT US

©2017 Novina Lab at Dana-Farber Cancer Institute